Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.71 |
| ▸ | HTR2C | P28335 | 9/20 | 0.71 |
| ▸ | HTR2B | P41595 | 8/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298572 | 0.85 | HTR2A (0.73) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| Water SCHEMBL16701244 | 0.84 | HTR2A (0.71) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL2368756 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL3757689 | 0.81 | HTR2A (0.71) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| Hydrochloric Acid SCHEMBL27967632 | 0.79 | HTR2A (0.69) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL173414 | 0.75 | HTR2A (0.58) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL1907938 | 0.74 | HTR2A (0.62) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL170990 | 0.73 | HTR2C (0.59) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL2477900 | 0.72 | HTR2A (0.58) | HTR2AHTR2CHTR2BPNMTADRB1 | |
| SCHEMBL173952 | 0.71 | HTR2A (0.57) | HTR2AHTR2CHTR2BPNMTADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038701-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8802845-B2 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto | Arena Phamaceuticals, Inc. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8501935-B2 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130178619-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-07-11 | — | — | US | disclosed |
| US-20120283431-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2518053-A1 | PROCESS FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | Arena Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2471779-A1 | Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8168782-B2 | synthesis of lorcaserin | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178619-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | HTR2C, HTR3C, HTR1A | HTR2A 12/4885HTR2C 1/4885HTR2B 17/4885 |
| US-20150038701-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | HTR2C, HTR3C, HTR1A | HTR2A 12/4885HTR2C 1/4885HTR2B 17/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | HTR2A 12/4885HTR2C 1/4885HTR2B 17/4885 |
| US-20120283431-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | HTR2C, HTR3C, HTR1A | HTR2A 12/4885HTR2C 1/4885HTR2B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.